Serious hemorrhagic cerebral infarction in patients receiving the drug has been reported. The diagnosis of cerebral thrombosis should be fully confirmed in the patient to be treated in order to avoid use of the drug in patients with cerebral embolisms who are apt to develop hemorrhagic cerebral infarction on thrombolytic therapy.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
